Tobias HÃ¶lscher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7177126/publications.pdf

Version: 2024-02-01

53	1,585	279798	315739
papers	citations	23 h-index	38 g-index

62	62	62	2040
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.8	118
2	Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. Radiotherapy and Oncology, 2004, 72, 1-13.	0.6	116
3	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. Journal of Clinical Oncology, 2015, 33, 4158-4166.	1.6	99
4	Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiotherapy and Oncology, 2003, 69, 121-125.	0.6	89
5	Additional PET/CT in week 5â€“6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiotherapy and Oncology, 2008, 88, 335-341.	0.6	74
6	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics, 2021, 11, 7844-7868.	10.0	70
7	Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. Radiotherapy and Oncology, 2006, 78, 123-130.	0.6	66
8	A diseaseâ€specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: Results of a randomized, controlled, multicenter trial. Cancer, 2013, 119, 3343-3353.	4.1	66
9	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. European Urology, 2021, 80, 306-315.	1.9	64
10	Neoadjuvant Capecitabine Combined with Standard Radiotherapy in Patients with Locally Advanced Rectal Cancer. Strahlentherapie Und Onkologie, 2008, 184, 450-456.	2.0	46
11	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiotherapy and Oncology, 2005, 76, 206-212.	0.6	40
12	Hypofractionated radiotherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2017, 193, 1-12.	2.0	40
13	Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Theranostics, 2021, 11, 8027-8042.	10.0	39
14	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. European Urology, 2019, 75, 548-551.	1.9	36
15	Effects of radiotherapy on olfactory function. Radiotherapy and Oncology, 2005, 77, 157-163.	0.6	35
16	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	2.7	34
17	Intraindividual comparison of [68ÂGa]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Research, 2021, 11, 109.	2.5	32
18	PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1322-1323.	6.4	26

#	Article	IF	Citations
19	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 619-626.	2.0	26
20	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€“staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. European Urology Oncology, 2022, 5, 44-51.	5.4	26
21	Fractionation in prostate cancer â€“ Is it time after all?. Radiotherapy and Oncology, 2010, 96, 1-5.	0.6	24
22	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II. Radiotherapy and Oncology, 2010, 97, 36-39.	0.6	23
23	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. International Journal of Radiation Oncology Biology Physics, 2013, 87, 534-541.	0.8	23
24	First-In-Human Validation of CT-Based Proton Range Prediction Using Prompt Gamma Imaging in Prostate Cancer Treatments. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1033-1043.	0.8	23
25	Dualâ€timeâ€point ⁶⁴<scp>Cuâ€PSMA</scp>â€617â€<scp>PET/CT</scp> in patients suffering from prostate cancer. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 523-532.	1.0	22
26	Ultrahypofractionation of localized prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 89-96.	2.0	22
27	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiotherapy and Oncology, 2018, 126, 257-262.	0.6	19
28	Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization. Zeitschrift Fur Medizinische Physik, 2019, 29, 216-228.	1.5	19
29	Treatment of Bone Metastases in Urologic Malignancies. Urologia Internationalis, 2014, 93, 249-256.	1.3	18
30	The future of IGRT â€“ Cost Benefit Analysis. Acta OncolÃ³gica, 2008, 47, 1188-1192.	1.8	17
31	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 109-116.	2.0	14
32	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the <scp>SAKK</scp> 09/10 randomized trial on prostate cancer. BJU International, 2017, 120, E45-E51.	2.5	13
33	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. Acta OncolÃ³gica, 2019, 58, 916-925.	1.8	11
34	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	2.0	11
35	[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Research, 2020, 10, 135.	2.5	11
36	Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial.. Journal of Clinical Oncology, 2021, 39, 194-194.	1.6	10

#	Article	IF	Citations
37	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 589-597.	2.0	10
38	Differences in responses to nociceptive stimulation of the oral and aboral oesophagus. Journal of Clinical Neuroscience, 2003, 10, 223-225.	1.5	9
39	ï»¿68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.7	9
40	Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. Urology, 2016, 94, e1-e2.	1.0	8
41	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). Cancers, 2022, 14, 2073.	3.7	7
42	Rapidly Evolving Diffuse Omental Carcinomatosis of Prostate Cancer in 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2021, 46, e216-e217.	1.3	5
43	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.8	5
44	Hepatic Vascular Malformation Mimics PSMA-Positive Prostate Cancer Metastasis. Clinical Nuclear Medicine, 2020, 45, e283-e284.	1.3	4
45	Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2021, 39, 5010-5010.	1.6	3
46	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. Strahlentherapie Und Onkologie, 2021, 197, 993-1000.	2.0	3
47	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. Journal of Clinical Oncology, 2015, 33, 5038-5038.	1.6	2
48	Acceptance and efficacy of recommended adjuvant radiotherapy in patients with positive lymph nodes at radical prostatectomy: a preference-based study. World Journal of Urology, 2022, 40, 1463-1468.	2.2	2
49	Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer. Strahlentherapie Und Onkologie, 2012, 188, 1125-1132.	2.0	1
50	Modeling patterns of anatomical deformations in prostate patients undergoing radiation therapy with an endorectal balloon. , 2017, , .		1
51	OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oligometastatic prostate cancerâ€"A phase II trial.. Journal of Clinical Oncology, 2021, 39, 115-115.	1.6	1
52	OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial. Radiotherapy and Oncology, 2017, 123, S58-S59.	0.6	0
53	Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus ZÃ¶phel, Steffen LÃ¶ck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548â€"51. European Urology, 2019, 76, e103-e104.	1.9	0